Interferon and ribavirin-free therapy with sofosbuvir and daclatasvir in a real-life cohort of difficult-to-treat HIV/HCV-coinfected patients
M Mandorfer, S Steiner, P Schwabl, MC Aichelburg, K Grabmeier-Pfistershammer, A Rieger, M Trauner, T Reiberger, M Peck-Radosavljevic · Zeitschrift für Gastroenterologie · 2015 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: Despite promising results for the combination of sofosbuvir and daclatasvir (SOF/DCV) in patients with HCV-monoinfection, there are currently no reports on its use in HIV/HCV-coinfected patients (HIV/HCV). Aim: To investigate the use of SOF/DCV in HIV/HCV, who have an urgent need for effective treatment options. Methods: The DCV dose was adjusted to the antiretroviral therapy, as recommended by the European label. The following treatment durations were applied: HCV-genotype (HCV-GT)1/4 with cirrhosis and HCV-GT3: 24 weeks; HCV-GT1/4 without cirrhosis: 12 weeks; if HCV-RNA was detectable 4 weeks befor…
